Analysis of a safety run-in cohort from NIVEAU, a phase 3 study for patients with aggressive Non-Hodgkin lymphoma in first relapse or progression not eligible for High-Dose Chemotherapy (HDT) testing Nivolumab in combination with (R)-GemOx
2020
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI